Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock
1. Cogent priced a public offering of 22.2 million shares at $9 each. 2. The offering aims to raise approximately $200 million for development efforts. 3. Proceeds will support the launch of bezuclastinib and other candidates. 4. Underwriters granted a 30-day option for additional share purchases. 5. SEC filings for the offering were completed on July 8, 2025.